PMID- 33288609
OWN - NLM
STAT- MEDLINE
DCOM- 20201217
LR  - 20211204
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 12
DP  - 2020 Dec
TI  - Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients 
      With Castration-resistant Prostate Cancer.
PG  - 7101-7108
LID - 10.21873/anticanres.14739 [doi]
AB  - BACKGROUND/AIM: It has been reported that some adverse events (AEs) of 
      enzalutamide (ENZ) occur more frequently in Japanese patients with 
      castration-resistant prostate cancer (CRPC) due to higher steady-state trough 
      plasma concentrations of ENZ (C(SS, ENZ)) and its active metabolite (NDE), (C(SS, 
      NDE)). Thus, we investigated the efficacy, safety, and pharmacokinetics of ENZ in 
      Japanese patients with CRPC. PATIENTS AND METHODS: Fourteen patients were 
      administered ENZ at a standard dose (160 mg/day) or reduced doses (80 or 120 
      mg/day). Prostate-specific antigen (PSA), AEs, C(SS, ENZ), and C(SS, NDE) were 
      examined. RESULTS: A maximum PSA decrement of >/=50% from baseline was achieved in 
      92% of patients. AEs were few (>20%) and mild. No differences in C(SS, ENZ) and 
      C(SS, NDE) between other ethnic groups in previous literature and our subjects 
      was observed. CONCLUSION: ENZ shows adequate efficacy and safety in Japanese 
      patients with CRPC, even if administered at reduced doses in real-world 
      conditions.
CI  - Copyright (c) 2020 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Hori, Akiyo
AU  - Hori A
AD  - Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan.
FAU - Sahashi, Haruka
AU  - Sahashi H
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Sano, Sora
AU  - Sano S
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Matsumiya, Emiri
AU  - Matsumiya E
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Ariga, Maho
AU  - Ariga M
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Asano, Akari
AU  - Asano A
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Soda, Midori
AU  - Soda M
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan.
FAU - Goto, Chitoshi
AU  - Goto C
AD  - Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan.
FAU - Mizui, Takashi
AU  - Mizui T
AD  - Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan.
FAU - Komeda, Hisao
AU  - Komeda H
AD  - Department of Urology, Gifu Municipal Hospital, Gifu, Japan.
FAU - Kitaichi, Kiyoyuki
AU  - Kitaichi K
AD  - Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu 
      Pharmaceutical University, Gifu, Japan kitaichi@gifu-pu.ac.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Benzamides)
RN  - 0 (Nitriles)
RN  - 2010-15-3 (Phenylthiohydantoin)
RN  - 93T0T9GKNU (enzalutamide)
SB  - IM
MH  - Aged
MH  - Benzamides
MH  - Cohort Studies
MH  - Humans
MH  - Japan
MH  - Male
MH  - Nitriles
MH  - Phenylthiohydantoin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/epidemiology
OTO - NOTNLM
OT  - Enzalutamide
OT  - N-desmethyl enzalutamide
OT  - castration-resistant prostate cancer
OT  - pharmacokinetics
OT  - reduced dose
EDAT- 2020/12/09 06:00
MHDA- 2020/12/18 06:00
CRDT- 2020/12/08 05:39
PHST- 2020/10/09 00:00 [received]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2020/12/08 05:39 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/18 06:00 [medline]
AID - 40/12/7101 [pii]
AID - 10.21873/anticanres.14739 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Dec;40(12):7101-7108. doi: 10.21873/anticanres.14739.